ES2362062B1 - NEW CONJUGATES AND COMPOSITIONS FOR IMMUNOTHERAPY AND ANTI-TUMORAL TREATMENT. - Google Patents

NEW CONJUGATES AND COMPOSITIONS FOR IMMUNOTHERAPY AND ANTI-TUMORAL TREATMENT. Download PDF

Info

Publication number
ES2362062B1
ES2362062B1 ES200931158A ES200931158A ES2362062B1 ES 2362062 B1 ES2362062 B1 ES 2362062B1 ES 200931158 A ES200931158 A ES 200931158A ES 200931158 A ES200931158 A ES 200931158A ES 2362062 B1 ES2362062 B1 ES 2362062B1
Authority
ES
Spain
Prior art keywords
compositions
immunotherapy
immune response
new conjugates
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn - After Issue
Application number
ES200931158A
Other languages
Spanish (es)
Other versions
ES2362062A1 (en
Inventor
Pedro Berraondo Lopez
Jessica Fioravanti
Jose Medina Echeverz
Ignacio Javier Melero Bermejo
Maria Del Carme Ochoa Nieto
Francisco De As Palazon Garcia
Silvia Bulfone-Paus
Erwuin Duitman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PROYECTO DE BIOMEDICINA CIMA S.L. (Titular al 50%)
Forschungszentrum Borstel Leibniz Lungenzentrum FZB
Proyecto de Biomedicina CIMA SL
Original Assignee
PROYECTO DE BIOMEDICINA CIMA S.L. (Titular al 50%)
Forschungszentrum Borstel Leibniz Lungenzentrum FZB
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200931158A priority Critical patent/ES2362062B1/en
Application filed by PROYECTO DE BIOMEDICINA CIMA S.L. (Titular al 50%), Forschungszentrum Borstel Leibniz Lungenzentrum FZB, Proyecto de Biomedicina CIMA SL filed Critical PROYECTO DE BIOMEDICINA CIMA S.L. (Titular al 50%)
Priority to ES10814739.8T priority patent/ES2463016T3/en
Priority to BR112012013868A priority patent/BR112012013868A8/en
Priority to RU2012129208/10A priority patent/RU2597989C2/en
Priority to US13/514,855 priority patent/US8771664B2/en
Priority to CN201080061939.9A priority patent/CN102753574B/en
Priority to AU2010329805A priority patent/AU2010329805B2/en
Priority to CA2783876A priority patent/CA2783876C/en
Priority to JP2012542587A priority patent/JP5784626B2/en
Priority to PCT/ES2010/070818 priority patent/WO2011070214A2/en
Priority to MX2012006691A priority patent/MX2012006691A/en
Priority to EP10814739.8A priority patent/EP2511294B1/en
Publication of ES2362062A1 publication Critical patent/ES2362062A1/en
Application granted granted Critical
Publication of ES2362062B1 publication Critical patent/ES2362062B1/en
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A61K47/48269—
    • A61K47/48276—
    • A61K47/48346—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con composiciones que presentan capacidad de promover tanto la respuesta inmune innata como de la respuesta inmune adaptativa en un sujeto basadas en el uso conjunto de ApoA, interleuquina 15 y del dominio sushi de la cadena alfa del receptor de IL 15, así como al uso de estas composiciones para estimular la respuesta inmune en un paciente y en métodos terapéuticos para el tratamiento de enfermedades infecciosas y neoplásicas.The present invention relates to compositions that have the ability to promote both the innate immune response and the adaptive immune response in a subject based on the joint use of ApoA, interleukin 15 and the sushi domain of the alpha chain of the IL 15 receptor, as well as the use of these compositions to stimulate the immune response in a patient and in therapeutic methods for the treatment of infectious and neoplastic diseases.

ES200931158A 2009-12-11 2009-12-11 NEW CONJUGATES AND COMPOSITIONS FOR IMMUNOTHERAPY AND ANTI-TUMORAL TREATMENT. Withdrawn - After Issue ES2362062B1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES200931158A ES2362062B1 (en) 2009-12-11 2009-12-11 NEW CONJUGATES AND COMPOSITIONS FOR IMMUNOTHERAPY AND ANTI-TUMORAL TREATMENT.
JP2012542587A JP5784626B2 (en) 2009-12-11 2010-12-10 Novel conjugates and compositions for immunotherapy and anti-tumor therapy
RU2012129208/10A RU2597989C2 (en) 2009-12-11 2010-12-10 Conjugates and compositions for immunotherapy and anticancer treatment
US13/514,855 US8771664B2 (en) 2009-12-11 2010-12-10 Compositions comprising apolipoprotein A polypeptide and interleukin 15, and methods of treatment using the same
CN201080061939.9A CN102753574B (en) 2009-12-11 2010-12-10 Novel conjugates and compositions for immunotherapy and antineoplastic treatment
AU2010329805A AU2010329805B2 (en) 2009-12-11 2010-12-10 New conjugates and compositions for immunotherapy and anti-tumoral treatment
ES10814739.8T ES2463016T3 (en) 2009-12-11 2010-12-10 Conjugates and compositions for immunotherapy and anti-tumor treatment
BR112012013868A BR112012013868A8 (en) 2009-12-11 2010-12-10 composition, fusion protein, polynucleotide, gene vector or construct, host cell, pharmaceutical composition, in vitro method and use of a composition.
PCT/ES2010/070818 WO2011070214A2 (en) 2009-12-11 2010-12-10 Novel conjugates and compositions for immunotherapy and antineoplastic treatment
MX2012006691A MX2012006691A (en) 2009-12-11 2010-12-10 Conjugates and compositions for immunotherapy and anti-tumor treatment.
EP10814739.8A EP2511294B1 (en) 2009-12-11 2010-12-10 Conjugates and compositions for immunotherapy and anti-tumoral treatment
CA2783876A CA2783876C (en) 2009-12-11 2010-12-10 New conjugates and compositions for immunotherapy and antitumoral treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200931158A ES2362062B1 (en) 2009-12-11 2009-12-11 NEW CONJUGATES AND COMPOSITIONS FOR IMMUNOTHERAPY AND ANTI-TUMORAL TREATMENT.

Publications (2)

Publication Number Publication Date
ES2362062A1 ES2362062A1 (en) 2011-06-28
ES2362062B1 true ES2362062B1 (en) 2012-05-09

Family

ID=44144475

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200931158A Withdrawn - After Issue ES2362062B1 (en) 2009-12-11 2009-12-11 NEW CONJUGATES AND COMPOSITIONS FOR IMMUNOTHERAPY AND ANTI-TUMORAL TREATMENT.

Country Status (1)

Country Link
ES (1) ES2362062B1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097283B2 (en) * 2004-01-15 2012-01-17 Mount Sinai School Of Medicine Methods and compositions for imaging
CA2657277C (en) * 2006-07-13 2015-11-24 Upperton Limited Process for preparing particles of proteinaceous material
KR100817024B1 (en) * 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 Composite for specifically transporting a nucleic acid or a drug to liver and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
ES2362062A1 (en) 2011-06-28

Similar Documents

Publication Publication Date Title
AU2010329805B2 (en) New conjugates and compositions for immunotherapy and anti-tumoral treatment
CY1123404T1 (en) ANTI-GIRT ANTIBODIES
LTC2435432I2 (en) Apoptosis-causing agents for the treatment of cancer and immune and autoimmune diseases
GT201200258A (en) COMPOSITIONS OF ANTI-FACTOR ANTI-FACTOR OF NERVOUS GROWTH (NGF)
IN2012DN02736A (en)
MX2018009945A (en) Novel compositions and methods for the treatment of immune related diseases.
DK2459216T3 (en) IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS
BR112013032717A2 (en) glucagon / glp-1 receptor coagonists
MX2009011500A (en) Anti-mdl-1 antibodies.
UY35682A (en) ANTI-ACTIVINE ANTIBODIES A AND USES OF THE SAME
MX2011010977A (en) Combination immunotherapy compositions against cancer and methods.
CL2012001950A1 (en) Use of a probiotic bacterial strain in the manufacture of a medicament or nutritional composition in humans or animals to alter sleep patterns
CO6400149A2 (en) MYTHATIN LINK PROTEINS
EA201101530A1 (en) IMMUNONANOTHERAPY, PROVIDING TH1-DISPERSED RESPONSE
TW200637614A (en) Bendamustine pharmaceutical compositions
MX345535B (en) Partially saturated tricyclic compounds and methods of making and using same.
MX2021000715A (en) Compositions and methods for treating metabolic disorders.
BR112012016853A2 (en) "pharmaceutical compositions for oral administration of insulin peptides".
AR091422A1 (en) PEPTIDIC ANALOGS OF EXENDINA 4
MX2014008705A (en) Tricyclic sulfone compounds and methods of making and using same.
UA102432C2 (en) Neuropeptide y-cytotoxic conjugates
MX2015005732A (en) Tricyclic compounds and methods of making and using same.
MX2013010367A (en) Compositions and methods for the therapy and diagnosis of influenza.
BR112015010639A2 (en) lactobacillus rhamnosus to reduce body fat accumulation
CR20170470A (en) TREATMENT OF PATIENTS WITH MELLITUS DIABETES TYPE 2

Legal Events

Date Code Title Description
PC2A Transfer of patent
FG2A Definitive protection

Ref document number: 2362062

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20120509

FA2A Application withdrawn

Effective date: 20121107